Biomea Fusion (BMEA) Status update summary

Clinical landscape and patient management

• Diabetes care is evolving with faster adoption of new therapies, especially GLP-1s, driven by patient demand and increased GP familiarity.

• In specialty practice, 35%-40% of type 2 diabetes patients are on GLP-1s, with higher rates in regions with better access.

• About 50%-60% of type 2 patients in specialty care are on insulin, with 20% using multiple daily injections.

• Treatment failure with GLP-1s is common over time, leading to the need for additional agents or insulin.

• Short-term, disease-modifying therapies are highly desirable to reduce lifelong medication burden.

Mechanism and potential of icovamenib

• Icovamenib targets menin, a regulator of beta cell proliferation, aiming to restore endogenous insulin production.

• The approach is rooted in human biology, mimicking processes seen in pregnancy and lactation.

• Unlike current therapies, icovamenib may offer durable glycemic control after a short treatment course by regenerating beta cells.

• Safety concerns about tumorigenesis were addressed by robust monitoring, with no evidence of neuroendocrine tumor growth.

• Glucose-dependent action reduces hypoglycemia risk, and endogenous insulin production is favored over exogenous approaches.

Clinical data and trial insights

• In type 1 diabetes, COVALENT-112 showed a 52% increase in mean C-peptide at week 12, with some decline by week 52 but sustained benefit.

• C-peptide improvement is seen as more predictive of long-term outcomes than A1C reduction in type 1 diabetes.

• Early phase type 2 data (COVALENT-111) showed A1C reductions of 1.2%-1.5% and C-peptide increases of 24%-35% at 52 weeks, comparable to early GLP-1s.

• Clean safety profile with no grade 3 adverse events reported in early trials.

• Ongoing and future trials will explore combination with immunosuppressants and positioning relative to GLP-1s.